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ABSTRACT
The cyclin-dependent kinase (cdk) inhibitors are key regulators of cell
cycle progression. p27 and p21 are members of the Cip/Kip family of cdk
inhibitors and regulate cell growth by inactivating cell cycle stage-specific
CDK-cyclin complexes. Because down-regulation of osteoprogenitor pro-
liferation is a critical step for osteoblast differentiation, we investigated
expression of p27 and p21 during development of the osteoblast phenotype
in rat calvarial osteoblasts and in proliferating and growth-inhibited
osteosarcoma ROS 17/2.8 cells. Expression of these proteins indicates that
p21, which predominates in the growth period, is related to proliferation
control. p27 levels are maximal postproliferatively, suggesting a role in the
transition from cell proliferation to osteoblast differentiation. We directly
examined the role of p27 during differentiation of osteoprogenitor cells
derived from the bone marrow (BM) of p272/2 mice. BM cells from p27
null mice exhibited increased proliferative activity compared with BM
cells from wild-type mice and formed an increased number and larger size
of osteoblastic colonies, which further differentiated to the mineralization
stage. Although p272/2 adherent marrow cells proliferate faster, they
retain competency for differentiation, which may result, in part, from
observed higher p21 levels compared with wild type. Histological studies
of p272/2 bones also showed an increased cellularity in the marrow cavity
compared with the p271/1. The increased proliferation in bone does not
lead to tumorigenesis, in contrast to observed adenomas in the null mice.
Taken together, these findings indicate that p27 plays a key role in
regulating osteoblast differentiation by controlling proliferation-related
events in bone cells.
INTRODUCTION
In eukaryotic cells, progression through the cell cycle is regulated
by cdks3 and their activating subunits, the cyclins (1, 2). cdks mediate
phosphorylation of regulatory factors that contribute to control of
transitions between sequential phases of the cell cycle (3). Different
combinations of cyclins and cdks are required at appropriate times for
orderly progression through the cell cycle. However, their activation
is regulated by feedback mechanisms that prevent premature entry of
cells into the next stage of the cell cycle, before completion of
necessary macromolecular events (4).
Two families of protein inhibitors that negatively regulate activity
of cyclin-cdk complexes have been identified in mammalian cells.
The Cip/Kip family includes p21Cip1 (also designated WAF1; Refs.
5–9), p27Kip1 (10, 11), and p57Kip2 (12, 13). The second family
includes p18, p19, p15, and p16 (14–17). Cip/Kip family members
inhibit the kinase activities of cdk2 in complex with cyclin A or E and
cdk4/cdk6 in complex with cyclins D1, D2, or D3. The inhibition of
kinase activity by the Cip/Kip proteins provides a mechanism for
negative regulation of cell proliferation that is associated with cell
cycle arrest, differentiation, and/or apoptosis. In many different cell
types, p21Cip1 expression is induced in response to DNA damage to
promote cell cycle arrest (5, 18), whereas p27Kip1 induction is ob-
served in several tissues after growth inhibition, mediated either by
the growth factor TGF-b or by serum deprivation (10, 11, 19).
Several recent studies suggest that Cip/Kip CDIs may support
differentiation of a variety of cell types (reviewed in Ref. 20). MyoD,
a skeletal muscle-specific bHLH transcription factor that induces
terminal cell cycle arrest associated with skeletal muscle differentia-
tion, has been shown to induce the levels of p21Cip (21). In situ
hybridization of developing mouse embryos demonstrates that p21
mRNA is localized to tissues that primarily contain postmitotic dif-
ferentiated cells (22). p27Kip1 may be required for restriction point
control to exit the cell cycle; the levels of p27Kip1 are increased in
fibroblasts deprived of serum mitogens and consequently arrested in
G1 (23). Mice nullizygous for p27 demonstrate a number of pheno-
types related to defects in differentiation, including a body size
one-third larger than the WT controls, female sterility associated with
a defect in luteal cell differentiation, and pituitary adenomas (24–26).
p57Kip2 expression is also associated with terminally differentiated
cells (12, 13), including rat calvarial osteoblasts (27), suggesting
linkage to exit from the cell cycle and/or expression of phenotypic
properties. Indeed, mice lacking p27KIP2 display altered proliferation
and differentiation of several mesenchymal cell types, indicating
muscle, cartilage, and ossification defects (28).
During bone formation, differentiating osteoblasts progress through
well defined stages of maturation, including cell proliferation, matrix
synthesis, and a final stage of differentiation concomitant with extra-
cellular matrix mineralization. This developmental sequence is sup-
ported by a temporal expression of cell growth and phenotype-related
genes (29). Previous studies from our laboratory have demonstrated
selective expression of several different cyclins and cdks during
osteoblast maturation (30, 31). For example, cyclins B and E are
selectively up-regulated after cessation of proliferation in mature
osteoblasts undergoing matrix mineralization. Therefore, there is a
requirement to control the activities of cell cycle regulatory factors
(such as the cyclins) during the growth and postproliferative periods
of osteoblasts.
To understand the mechanisms by which osteoblast growth is
down-regulated at key transition points from proliferation and growth
arrest to differentiation, we have evaluated the roles of p21 and p27 in
regulating development of the osteoblast phenotype. We show that
during osteoblast differentiation, p21 is proliferation-related, whereas
p27 is more abundant in mature osteoblasts. We established that
ablation of p27 results in precocious proliferation of BM-derived
osteoprogenitor cells and apparent acceleration of osteoblast differ-
entiation. Our studies of the p27 null mice suggest a key role for p27
in regulating the proliferation to differentiation transition in osteo-
blasts.
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MATERIALS AND METHODS
Cell Cultures. Primary cell cultures were established from animals main-
tained in accordance with NIH guidelines for the care and use of laboratory
animals. Normal osteoblasts were isolated from fetal rat calvariae (21 days of
gestation) and maintained in MEM (Life Technologies, Inc., Grand Island,
NY) supplemented with 10% FCS (Atlanta Biological, Norcross, GA), 200 mM
L-glutamine, and antibiotics (500 mM penicillin and 500 mM streptomycin;
Sigma Chemical Co., St. Louis, MO). Media were changed every 2 days until
confluent. For mineralization, cells were fed with the same media supple-
mented with ascorbic acid (50 mg/ml) and b-glycerophosphate (10 mM; Sigma
Chemical Co.; Ref. 32). These ROBs were treated with 100 pM TGF-b or 10-8
M 1,25(OH)2D3 (Sigma Chemical Co.) for 24 h before collection for protein
assays. Both factors were added on day 7 (proliferation period), day 11 (GI,
MM stage), or day 21 (differentiation, mineralization period).
Primary stromal cells were cultured after flushing the BM from femurs and
tibias of p271/1 (WT) or p272/2 (KO) male mice, 6 weeks of age, by
previously described procedures for osteoprogenitor enrichment in the plastic
adherent population of mouse marrow (33, 34). Cells were rinsed extensively
and passed through a 0.45-mm filter before seeding at 3 3 106 cells/well into
6-well plates. Cells were maintained in culture with a MEM supplemented
with 20% heat-inactivated FCS. After 4 days, nonadherent cells were removed,
and media were changed every other day to complete media containing 50 mM
ascorbic acid and 10 mM b-glycerophosphate to induce mineralization. The
adherent marrow stromal cells were cultured for 7 or 20 days.
ROS 17/2.8 Cells (35) were maintained in F12 (Life Technologies, Inc.)
supplemented with 5% FCS. Cells were plated at a density of 7 3 105/100-mm
dish and collected during the proliferation and density-dependent growth
inhibition periods. Growth inhibition was achieved by plating the cells at a
higher density, 1 3 106/100 mm-dish and harvesting at confluency.
AP. AP activity was assessed cytochemically in BM-cultured cells from
WT and p272/2 mice maintained in mineralization media for 7 or 20 days. The
cell layers were washed twice with ice-cold PBS and fixed with 2% parafor-
maldehyde before staining. Cells were incubated 15–30 min at 37°C in Tris
buffer containing naphthol AS-BI phosphate and Fast Red Violet LB-salt using
Sigma reagents.
Calcium Measurement. Mineral deposition in the BMC cultures was
identified histochemically by staining 2% paraformaldehyde-fixed cells with
von Kossa solution (32). Total calcium content in the extracellular matrix was
determined at day 7 and day 20 of culture. After dissolving the matrix in 0.5
N HCl (1 ml/well), cells were sonicated and an aliquot was used for calcium
determination calorimetrically using a calcium detection kit (Sigma Chemical
Co.).
DNA Content Analysis. Cells were scraped off in 0.5 N HCl and soni-
cated. DNA was precipitated using 10% perchloroacetic acid and resuspended
in 10 mM Tris-1 mM EDTA buffer (pH 7.5) before measurement. Total DNA
content was quantified fluorimetrically using a DyNA quart 200 fluorimeter
(Pharmacia Biotechnology, San Francisco, CA). An aliquot of DNA solution
was incubated with Hoechst 33258 reagent (36), and fluorescence was meas-
ured at excitation and emission wavelengths of 350 nm and 455 nm, respec-
tively. Bovine thymus DNA was used as standard.
Western Blot Analysis. Cells were harvested in ice-cold PBS and centri-
fuged 10 min at 2500 3 g. Cell pellets were then resuspended in EBC lysis
buffer (50 mM Tris-HCl, 120 mM NaCl, 0.5% NP40, 1 mM EDTA, 10 mg/ml
trypsin inhibitor, 10 mg/ml leupeptin, 10 mg/ml pepstatin, 20 mg/ml TPCK, 1
mM DTT, and 1 mM PMSF), in which they were incubated for 15 min on ice,
then centrifuged for 10 min at 2000 3 g. The supernatants were collected for
Western analysis. After total protein concentrations were quantified by Brad-
ford assay, 25 or 30 mg whole cell extract protein were subjected to SDS-
PAGE (12%), followed by electroblotting onto polyvinylidene difluoride
membranes (Bio-Rad Laboratories, Rockville Center, NY) or Immobilon P
membranes (Millipore Corp., Bedford, MA). Immunodetection was performed
with the enhanced chemiluminescence ECL-Plus, following the manufactur-
er’s instructions (Amersham Corp., Arlington Heights, IL). Proteins were
detected using specific polyclonal antibodies to p15, p16, p21, and p27
generated to the COOH terminus of each protein (Santa Cruz Biotechnology,
Santa Cruz, CA).
Histological Analysis. Tibia and femur of WT and p27 null mice, 4–5
weeks of age, were fixed in 2.5% paraformaldehyde, demineralized in 10%
EDTA (pH 7.5), and prepared for paraffin embedding. Longitudinal sections
were deparaffinized by standard procedures and stained with either H&E or
with Toluidine blue. Multiple serial sections of bones were examined from WT
and p272/2 mice (n 5 2), with each p271/1 and p272/2 pair from the same
litter. Comparisons of marrow volume, growth plates, trabeculae density, and
diaphyseal cortical bone width were made on similar bone planes.
RESULTS
Stage-specific Expression of CDIs during Development of the
Osteoblast Phenotype. We assessed the levels of p21 and p27 in
primary cultured rat calvarial osteoblasts during the principal devel-
opmental stages of growth and differentiation: the proliferation period
(3 days of culture), MM period (11 days), and the terminally differ-
entiated mineralization stage (22 days). To evaluate cellular protein
levels in relation to growth and differentiation of osteoblasts, we
monitored the consequential effects of physiological regulators of
osteoblast maturation. Fig. 1 shows that during osteoblast differenti-
ation, basal levels of p21 are high in proliferating cells and down-
regulated in the immediate postproliferative MM period, and that,
subsequently, p21 exhibits increased expression. Levels of p27 are
low in proliferating normal osteoblasts and substantially increased in
postproliferative osteoblasts during differentiation.
TGF-b treatment of osteoblasts during the proliferation period
results in loss of competency for differentiation at later postconfluent
stages. TGF-b initially arrests growth and then exerts a mitogenic
effect on osteoblasts (37–39). To examine the mechanisms associated
with TGF-b blockade of osteoblast differentiation, we assessed the
effect of TGF-b on expression of p21 and p27 CDIs. TGF-b does not
alter p21 expression in the proliferative period, whereas it slightly
reduces p21 levels at the differentiation stage in osteoblasts. p27
levels have been reported to be enhanced in several in vitro models
that are GI by TGF-b treatment (40). Although low levels of p27 are
found in proliferating cells, TGF-b has a slight inhibitory effect on
p27 levels in proliferating osteoblasts. In contrast, in postproliferative
mature osteoblasts, TGF-b slightly increased p27 expression.
Vitamin D promotes osteoblast differentiation (41); thus, for
24 h, we treated primary osteoblasts with 10-8 M 1,25(OH)2D3 to
observe the effects on p21 and p27 expression. Vitamin D3 sig-
nificantly increases p21 cellular levels in proliferating cells, but
inhibits p21 expression in differentiated osteoblasts. Vitamin D
treatment induced a significant increase in p27 levels in prolifer-
ating cells and, to a lesser extent, in differentiated cells. These
observations are consistent with the known antiproliferative effect
of 1,25(OH)2D3 on these osteoblasts (42). Taken together, our
findings show that in ROB cells, p21 and p27 have an opposite
pattern of expression during osteoblast differentiation. p21 seems
to be a proliferation-related CDI, reflected by reduced expression
during osteoblast differentiation. In contrast, p27 is more abundant
after exit from the cell cycle, during postproliferative osteoblast
differentiation. These results support the hypothesis that p27 may
regulate late stages of osteoblast maturation.
We also assessed expression of p21 and p27 in ROS 17/2.8 cells,
which exhibit abrogated growth-differentiation relationships when
compared with normal diploid osteoblasts. ROS 17/2.8 cells ex-
press differentiation genes constitutively, but the bone phenotype
mineralized matrix is lacking in these cultures. However, some
phenotypic markers are up-regulated at confluency (43). Fig. 2
shows that basal levels of p21 are ;2-fold greater in proliferative
cells compared with confluent GI cells. The expression of p27 is
significantly higher in GI cultures than in the proliferating cells.
Thus, similar to normal osteoblasts (ROBs), p21 seems to be a
proliferation-related CDI, whereas p27 expression is coupled to the
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mature osteoblast phenotype in the GI ROS 17/2.8 cells. However,
only subtle differences in response to TGF-b and vitamin D are
observed when compared with ROB cells. The effect of TGF-b on
p21 in proliferating ROS 17/2.8 cells is similar to that observed in
Mv1LU cells (44). In contrast, vitamin D decreased p21 in GI
cells. Consistent with vitamin D3 inhibition of cell growth con-
comitant with induction of bone phenotypic differentiation-related
genes in osteosarcoma cells (43), p27 increased significantly in
proliferating cells after treatment with Vitamin D3.
Bones of p27 Null Mice Are Larger than Those of WT Litter-
mates. Although p27 null mice are from 20–40% larger in size than
WT littermates, X-rays of the skeleton revealed normal anatomy (24).
Overall tibia and femoral bone lengths of p272/2 mice are greater
than that of WT mice (24). In our studies, we examined cell and tissue
organization of bone. Fig. 3A reveals the increased size of the bone
and increased width of diaphyseal cortical bone shafts of KO mice
compared with WT mice (Fig. 3B). Measurements along the bone
shaft ranged from 31–40 mm in WT bone and 60.5–70 mm in p272/2
mice. Both osteoblasts and osteoclasts on trabecular bone surfaces
were of normal appearance in bones of p272/2 mice (data not shown).
The overall width of the growth plate is very similar between WT and
p27 null mice, with no noted disorganization of the maturation zones
(Fig. 3, C and D), although in some sections the proliferating zone of
chondrocytes appears slightly larger. A striking difference between
WT and null mice in long bone appearance was observed in cellularity
of the marrow cavity (Fig. 3, A and B). Cellular density of the marrow
was greater in p272/2 mice in all sections examined. Notably, the
marrow of WT mice shows a typical morphological appearance (Fig.
3B), whereas densely packed cells are observed throughout the mar-
row and particularly along the endosteal surfaces of p272/2 mice (Fig.
3A).
p27Kip1 Regulates the Number of Osteoprogenitor Cells in BM.
To address an involvement of p27 in the development of the preos-
teoblast phenotype, we examined the competency of osteoprogenitor
cells from p272/2 mice compared with p271/1 mice to differentiate
using a BMC culture model. The adherent marrow cell population
forms cell colonies that can be directed to different mesenchymal cell
lineages dependent on the culture conditions (45). When ascorbic acid
and b-glycerophosphate are included in the medium, osteogenic dif-
ferentiation occurs. Fig. 4 shows staining of the cells for AP, an early
marker of osteoblasts, at 7 and 20 days of culture. In 7-day cultures
derived from BM of p272/2 mice, there is an increased representation
of AP-stained colonies compared with cultures from WT mice (Fig.
4A). These differences between the two populations of cells persist
after 20 days of culture (Fig. 4B) and reflect both an increased number
and size of the osteogenic colonies. The results suggest an accelerated
maturation of osteoprogenitors from the p27 null mice relative to
those from the p27 WT mice.
Marrow-derived osteoprogenitors from p272/2 mice also show
earlier mineralization of the extracellular matrix, compared with
WT animals. von Kossa silver staining indicates that after 20 days
of culture, osteogenic colonies in the p272/2 cultures are miner-
alized, whereas those formed from WT cells have not yet advanced
to this final stage of osteoblast maturation (data not shown). We
confirmed these qualitative observations by determining the total
calcium content of the mineralized extracellular matrix. Fig. 5
shows absence of calcium on day 7 when cells are proliferating and
an increased calcium concentration (21-fold) on day 20 in the
p272/2 cell layers, compared with the WT-derived cell cultures.
To determine whether the observed increase in the number of
osteogenic colonies is due to a difference in cell proliferation and/or
maturation, we assayed the DNA content in WT-derived cells com-
pared with p272/2-derived cells after 7 days and 20 days of culture.
Fig. 6 shows that at 7 days, p272/2-derived cell cultures contain
significantly higher amounts of DNA compared with the WT, indi-
Fig. 1. Reciprocal expression of p21 and p27 during osteoblast differentiation. Western
blot analysis of cell extracts from rat calvarial osteoblasts at three stages of differentiation:
proliferating (P), MM, and differentiation (D). Proteins (25 mg) were separated by
SDS-PAGE, and specific bands for p21 (top) and p27 (bottom) were detected using
polyclonal antibodies. Cells were treated (1 lane) for 24 h with either TGF-b (100 pM)
or vitamin D3 (10 nM).
Fig. 2. p27 expression is regulated in osteosarcoma cells. Western blot analysis using
30 mg of whole cell protein extracts from proliferating (P) and GI ROS 17/2.8 cells. Top,
specific bands for p21. Bottom, specific bands for p27. Cells were treated (1 lane) for 24 h
with either TGF-b (100 pM) or vitamin D3 (10 nM).
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cating a faster proliferation of cells lacking p27. After 20 days, the
levels of DNA were approximately the same in both KO- and
WT-derived cultures. Together, these results indicate that the p272/2
mice exhibit increased growth of osteogenic cells, which cease pro-
liferation and are competent to differentiate and develop the osteoblast
phenotype earlier than cells from WT mice.
Osteoblasts of p27 Null Mice Exhibit Elevated p21. p272/2
animals show increased body size relative to their p271/1 WT litter-
mates. Although no increase in systemic growth hormone or insulin-
like growth factor-I has been observed in these animals (24), p272/2
mice have larger long bones than WT mice and show increased
proliferation of marrow progenitor cells (see above). In several non-
osseous tissues, the absence of p27 leads to the development of
tumors; however, neither cartilage nor bone tissues show tumor ab-
normalities. To explore potential mechanisms by which cell growth is
regulated in osteoblasts in the absence of p27, we extracted total
proteins from cultured WT and p27 null BMCs at confluency and
assessed the expression of other CDIs. Western blot analysis shows,
as expected, that p27 is present only in extracts from WT cells (Fig.
7). We observed an increase in p21 levels in cells derived from
p272/2 compared with WT animals. The Ink family member p16 is
not expressed in mouse BMCs, and no differences in p15 expression
were observed between WT and p27 null cells (data not shown).
These results suggest a compensatory effect of p21 in the absence of
p27, which may contribute to regulation of osteoblast proliferation
and differentiation.
DISCUSSION
During bone formation, osteoblasts undergo a series of events
marked by phenotypic changes that contribute to tissue structure and
function. Proliferating osteoprogenitors must exit the cell cycle to
differentiate into mature osteoblasts, which will synthesize an extra-
cellular matrix competent for mineral deposition, and end their dif-
ferentiation as osteocytes in a mineralized matrix. In this study, we
have demonstrated that the CDI p27Kip1 is associated with the control
of the osteoblast growth differentiation transition based on the fol-
lowing observations: (a) mice lacking p27 seem to have in their
marrow an increased representation of osteoprogenitors, consistent
with larger bones; (b) although p21 predominates in proliferating cells
during development of the osteoblast phenotype in vitro, p27 is
preferentially expressed in the immediate postproliferative stage of
osteoblast maturation; (c) 1,25(OH)2D3, a potent inducer of osteoblast
differentiation, dramatically increases p27 expression during the
growth period; and (d) p27 appears in GI osteosarcoma cells.
It is well known that entry into and progression through the cell
cycle are promoted by cyclins and cdk complexes, which facilitate the
transition between different phases of the cell cycle. In earlier studies,
Fig. 3. Increased bone size and marrow cell density of p272/2 mice. Decalcified femur sections of p272/2 (A and C) and WT (B and D) mice, 5 weeks of age, from the same litter.
A and B, the diaphysis and marrow stained with H&E (magnification, 3200). C and D, the chondrocyte zones of the growth plate revealed by Toluidine blue staining (magnification,
3250).
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we reported a significant up-regulation of cyclin E in postproliferative
osteoblasts (30). Because cyclin E-Cdk complexes are targeted by the
Cip/Kip family of CDIs, which include p21 and p27, we investigated
these CDIs during growth and maturation of the osteoblast phenotype.
The observed protein levels at three stages of osteoblast differentia-
tion suggest that p21 expression is developmentally biphasic with
high levels in proliferating osteoblasts, a sharp decline in postprolif-
erative cells, and induction in more differentiated osteoblasts in the
mineralization period. The enhancement of p21 expression during
osteoblast proliferation after treatment with Vitamin D3 could be
explained by its effect on the p21 promoter, as described previously
(46). Notably, p21 is associated with protection of osteoblastic cells
against apoptosis (47); the appearance of p21 at the early mineraliza-
tion stage is consistent with this role during this period of osteoblast
maturation (48, 49).
The expression profile of p27 during development of the osteoblast
phenotype reflects a function in promoting the switch from prolifer-
ation to differentiation because it is abundantly expressed through the
MM and mineralization periods. A functional role for p27 in regulat-
ing initiation of differentiation as cells exit the cell cycle is further
supported by the enhancer effect of 1,25(OH)2D3, a differentiation-
promoting hormone and the absence of an effect on p27 levels by
TGF-b, which delays differentiation of osteoblasts. In epithelial cells,
TGF-b arrests the cell cycle and induces expression of p27 (10).
However, p27 declines on mitogenic stimulation of resting cells (50,
51), similar to the known effects of TGF-b in osteoblasts (38). Thus,
expression of p27 is tightly coupled to modifications in growth and
postproliferative differentiation. Consistent with these findings is a
related observation in a ROS cell line (UMR-106) treated with para-
thyroid hormone. Parathyroid hormone increases p27 expression in
these cells and blocks entry into S phase, inhibiting cell proliferation
Fig. 4. Formation of osteogenic colonies in BMCs from WT and p27 null mice. BMCs
were isolated from long bones of WT and p27 null mice (KO), 6 weeks of age. Cells were
seeded at a density of 3 3 106 cells/well in 6-well plates. Nonadherent hematopoietic cells
were removed after 4 days of culture in complete media, and mesenchymal cells were then
cultured for 7 days (A) or 20 days (B) in mineralization media containing ascorbic acid (50
mM) and b-glycerophosphate (10 mM). AP staining reveals colonies of osteoblastic cells.
Fig. 5. Mineralization of the osteogenic colonies in BM cultures from WT and p27
nullizygous mice. Cell layers of BM cultures derived from WT and p27 null mice (KO),
6 weeks of age, were harvested on day 20 for analysis of calcium content of the
extracellular matrix (as detailed in “Materials and Methods”). Values are means 6 SD of
duplicate determinations from wells (n 5 3) for different mice (n 5 3) from each group.
p, P , 0.01 significance by Student’s t test.
Fig. 6. Growth rate of marrow cells from WT and p27 null mice. Proliferation of p27 null
mice (KO) marrow-cultured cells is compared with WT by quantitating DNA levels in both
populations after 7 and 20 days of culture. DNA contents are 6 SD of samples (n 5 6) from
three different WT or p27 null mice. p, P , 0.01 significance by Student’s t test.
Fig. 7. p21 expression in p27 null mice compared with their WT littermates. Western blot
analysis of cell-extract proteins from confluent marrow cells cultured from two WT (M1 and
M2) and two p27 null (M3 and M4) mice. Proteins (30 mg) were loaded, and p21 (top) and p27
(bottom) were detected using specific antibodies (see “Materials and Methods”).
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(52). The up-regulation of p27, in concert with antiproliferative ef-
fects that correlate to expression of differentiation, is also observed in
our studies in GI ROS 17/2.8 cells. Our observations of increased p27
expression during maturation of the osteoblast phenotype strengthens
the growing concept that up-regulation of p27 is associated with
control of the proliferation to differentiation transition (53, 54).
We used a p27-nullizygous mouse model to explore the mecha-
nisms by which p27 regulates osteoblast differentiation. Mice lacking
p27 exhibit several abnormalities, among which are multiple adeno-
mas, female sterility, and enhanced growth. This increase in body
weight is not accompanied by an increase in serum levels of growth
hormone or insulin-like growth factor (24). Histological analysis
shows that p272/2 bones have essentially normal growth plates and
normal bone tissue morphology (Fig. 3). However, BM cavities ap-
pear proportionately larger, but with an increased marrow cell density,
observed particularly on the endosteal surface. This hypercellularity,
coupled with a significant 4–5-fold increase in formation of osteo-
genic colonies from marrow-derived adherent stromal cell cultures of
the p272/2 mice compared with p271/1 mice, may explain the
enhanced growth of the bones in the absence of p27.
We explored the mechanisms by which both the growth and dif-
ferentiation of adherent mesenchymal stem cells into osteoprogenitors
are regulated in the BM cultures from p272/2 and WT littermates.
BMCs from p272/2 animals proliferate at a faster rate, as demon-
strated by DNA measurements up to day 7. An increase in the number
of stromal colonies was observed. At this point in time, colonies also
exhibit osteogenic properties, becoming positive for AP, an early
marker of osteoblast differentiation. AP expression is induced in
postproliferative cells and is enhanced by secretion and formation of
the collagenous extracellular matrix (32, 55). In the p272/2 marrow
cultures, this first phase of osteogenesis is accelerated by the increased
number of cells that are promoted to the osteogenic phenotype.
Subsequent to this initial stage of early differentiation in the p272/2
cultures, mineralization of the extracellular matrix occurs because of
an adequate amount of matrix is produced by larger osteogenic
colonies in p272/2 cultures compared with WT. Thus, the second
stage of osteoblast differentiation proceeds at a normal rate.
Although p27 null animals present tumors in some tissues (26) due
to compromised control of proliferation, the enhanced growth of the
animals is not followed by development of osteosarcomas. The in-
crease in bone cell proliferation does not abrogate competency for
differentiation. In addition to signaling pathways arising from extra-
cellular matrix formation that contribute to differentiation, we found
that p21 expression is increased in p272/2 bone cells compared with
WT. Notably, Kiyokawa et al. (24) examined p21 levels in soft tissues
of p27 null mice and found no differences compared with WT. Thus,
the enhanced p21 expression in osteoblasts may provide a compen-
satory mechanism contributing to exit from the cell cycle in the
absence of p27, leading to differentiation and accounting for the
absence of tumors in bone. In vivo studies of double mutant p212/2,
p57-/1, and p272/2 with p576 show that the CDIs function redun-
dantly to control cell differentiation (56, 57). In these studies, we
provide evidence for p27Kip as a key regulator in the transition from
a proliferating osteoprogenitor to a postproliferative osteoblast. Thus,
it is possible that p57, implicated in skeletal development (28), may
also provide redundant activity in the regulation of osteoblast differ-
entiation.
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